In brief

BMJ 2003; 326 doi: (Published 03 May 2003) Cite this as: BMJ 2003;326:948

GlaxoSmithKline slashes cost of AIDS drug: GlaxoSmithKline is to reduce the cost of its antiretroviral drug Combivir (zidovudine and lamivudine) by almost half to $0.90 (£0.57; a0.82) a day in 63 developing countries. The company's move comes after pressure from the company's institutional investors to make access to AIDS drugs easier.

US sugar industry pressurises …

View Full Text

Log in

Log in through your institution


* For online subscription